Barcelona, June 1st 2018

SIGNIFICANT EVENT

Almirall: NDA submission to the US FDA for *Duaklir*

Almirall, S.A. ("Almirall"), pursuant to article 17 of Regulation (EU) No. 596/2014 on market abuse and article 228 of the restated text of the Securities Market Act approved by the Royal Legislative Decree 4/2015, of 23 October and related provisions, hereby announces that:

Our partner AstraZeneca submitted today a New Drug Application (NDA) submission to the US FDA for *Duaklir* (aclidinium bromide/formoterol 400/12mg).

The NDA submission is based on the positive results of the AMPLIFY study, announced on September 7th, 2017, that showed *Duaklir* significantly improved lung function in moderate to very severe stable COPD.

This NDA submission of aclidinium and formoterol combination and the potential FDA approval will contribute to making this treatment available to COPD patients in the US, and may trigger additional milestones from AstraZeneca to Almirall, according to the global collaboration between both companies signed on 1st November 2014.

We remain positive about this partnership that has allowed us to maximise the return and value of our assets and capabilities while it will keep improving the financial position of Almirall and contributing to the company's long-term growth.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com